Response of systemic onset juvenile rheumatoid arthritis to etanercept: Is the glass half full or half empty?

Journal of Rheumatology

Volumn 32, Issue 5, 2005, Pages 763-765

  Eberhard, B Anne ^a   Ilowite, Norman T ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; METHOTREXATE;

CLINICAL FEATURE; DRUG EFFICACY; EDITORIAL; JUVENILE RHEUMATOID ARTHRITIS; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; HUMANS; IMMUNOGLOBULIN G; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 18744402198     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (23)

1. Schaller JG. Juvenile rheumatoid arthritis. Pediatr Rev 1980; 2:163-74.
2. Svantesson H, Akesson A, Eberhardt K, Elbourgh R. Prognosis in juvenile rheumatoid arthritis with systemic onset. A follow-up study. Scand J Rheumatol 1983;129:139-44.
3. Spiegel LR, Schneider R, Lang BA, et al. Early predictors of poor functional outcome in systemic-onset juvenile rheumatoid arthritis: A multicenter cohort study. Arthritis Rheum 2000;43:2402-9.
4. Giannini EH, Brewer EJ, Kuzmina N, et al. Methotrexate in resistant juvenile rheumatoid arthritis: results of the U.S.A.U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group. N Engl J Med 1992;326:1043-9.
5. Woo P, Southwood TR, Prieur AM, et al. Randomised placebo-controlled crossover trial of low dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum 2000;43:1849-57.
6. Ruperto N, Murray KJ, Gerloni V, et al. Pediatric Rheumatology International Trials Organization. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004;50:2191-201.
7. al-Sewairy W, al-Mazyed A, al-Dalaan M, al-Balaa S, Bahabri S. Methotrexate therapy in systemic-onset juvenile rheumatoid arthritis in Saudi Arabia: a retrospective analysis. Clin Rheumatol 1998;17:52-7.
8. Kimura Y, Pinho P, Walco G, et al. Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis. J Rheumatol 2005;32:935-42.
9. Takei S, Groh D, Bernstein B, Shaham B, Gallagher K, Reiff A. Safety and efficacy of High dose etanercept in treatment of juvenile rheumatoid arthritis. J Rheumatol 2001;28:1677-80.
10. Horneff G, Schmeling H, Biedermann T, et al, for the Paediatric Rheumatology Collaborative Group. The German Etanercept Registry for Treatment of Juvenile Idiopathic Arthritis. Ann Rheum Dis 2004;63:1638-44.
11. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-9.
12. Mangge H, Gallistl S, Schauenstein K. Long-term follow-up of cytokines and soluble cytokine receptors in peripheral blood of patients with juvenile rheumatoid arthritis. J Interferon Cytokine Res 1999;19:1005-10.
13. Mangge H, Kenzian H, Gallistl S, et al. Serum cytokines in juvenile rheumatoid arthritis. Correlation with conventional inflammation parameters and clinical subtypes. Arthritis Rheum 1995;38:211-20.
14. Rooney M, David J, Symons J, Di Giovine F, Varsani H, Woo P. Inflammatory cytokine responses in juvenile chronic arthritis. Br J Rheumatol 1995;34:454-60.
15. Prieur AM, Roux-Lombard P, Dayer JM. Dynamics of fever and the cytokine network in systemic juvenile arthritis. Rev Rhum Engl Ed 1996;63:163-70.
16. de Benedetti F, Massa M, Robbioni P, Ravelli A, Burgio GR, Martini A. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 1991;34:1158-63.
17. Keul R, Heinrich PC, Muller-Newen G, Muller K, Woo P. A possible role for soluble IL-6 receptor in the pathogenesis of systemic onset juvenile chronic arthritis. Cytokine 1998;10:729-34.
18. Fishman D, Faulds G, Jeffrey R, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels and an association with systemic juvenile chronic arthritis. J Clin Invest 1998;102:1369-76.
19. Yokota S, Miyamae T, Imagawa T, et al. Phase II trial of anti-IL-6 receptor antibody (MRA) for children with systemic juvenile idiopathic arthritis [abstract]. Arthritis Rheum 2003;48 Suppl:S429.
20. Irigoyen PI, Olsen J, Hom C, Ilowite NT. Treatment of systemic juvenile rheumatoid arthritis with anakinra [abstract]. Arthritis Rheum 2004;50 Suppl:S437.
21. Henrickson M. Efficacy of anakinra in refractory systemic arthritis [abstract]. Arthritis Rheum 2004;50 Suppl:S438.
22. Verbsky JW, White AJ. Effective use of the recombinant interleukin1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol 2004;31:2071-5.
23. Pasqual V, Allantaz F, Arce E, et al. Dramatic clinical response to IL-1 blockade in systemic onset juvenile idiopathic arthritis [abstract]. Proceedings of the American College of Rheumatology 2004 Annual Meeting, San Antonio. Late Breaking Abstracts, 2004:L14.